Van ECK Associates Corp Invests $6.34 Million in Krystal Biotech, Inc. $KRYS

Van ECK Associates Corp purchased a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,071 shares of the company’s stock, valued at approximately $6,345,000. Van ECK Associates Corp owned about 0.06% of Krystal Biotech as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of KRYS. Royal Bank of Canada raised its holdings in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after buying an additional 964 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after buying an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after purchasing an additional 688 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Krystal Biotech during the 1st quarter valued at $218,000. Finally, Cetera Investment Advisers boosted its stake in Krystal Biotech by 107.9% during the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after acquiring an additional 2,255 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 1.5%

Shares of Krystal Biotech stock opened at $369.23 on Thursday. The firm has a market cap of $10.93 billion, a PE ratio of 46.27 and a beta of 0.54. Krystal Biotech, Inc. has a 12 month low of $136.73 and a 12 month high of $382.54. The stock has a 50 day moving average of $349.86 and a 200 day moving average of $306.35.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The company had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. As a group, equities research analysts forecast that Krystal Biotech, Inc. will post 7.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of several analyst reports. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Bank of America increased their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Citigroup raised their target price on Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. TD Cowen lifted their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $365.40.

Insider Buying and Selling

In related news, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares of the company’s stock, valued at $347,270. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.